30 April 2024 Recce Pharmaceuticals: Safety Committee Approves High Dose of 4,000mg in Phase I/II Urinary Tract Infection/Urosepsis Rapid Infusion Clinical Tria 0 minute read Pharma/Biotech By Cate Swannell Previous Post Next Post